论文部分内容阅读
米托蒽醌(Mitoxantrone)是蒽醌类抗癌药,其抗癌活性近似或略高于阿霉素(ADM),临床试用表明对乳腺癌、淋巴瘤及白血病有较好的疗效,对其他实体瘤的疗效还有待于临床的试验观察。我们自1987年5月应用上海医药工业研究院试制的米托蒽醌,作为恶性淋巴瘤及乳腺癌的术前化疗用药,作者初步探讨其近期疗效、病理改变与药理作用
Mitoxantrone is an anthraquinone anticancer drug with anticancer activity similar to or slightly higher than that of doxorubicin (ADM). Clinical trial shows that it has good curative effect on breast cancer, lymphoma and leukemia, The efficacy of solid tumors remains to be observed in clinical trials. We since May 1987 trial of the Shanghai Institute of Pharmaceutical Industry mitoxantrone, as a malignant lymphoma and breast cancer preoperative chemotherapy, the authors preliminary study of its immediate effect, pathological changes and pharmacological effects